Exploring all options to procure enough vaccines: KTR

Task Force also discussed with them various alternatives to drugs that are in high demand like Remdesivir

Hyderabad: Municipal Administration Minister KT Rama Rao said on Friday that the State government is exploring all possible options to procure a sufficient quantity of vaccines.

The Minister, who heads the Covid Task Force, discussed various alternatives to drugs that are in high demand like Remdesivir with representatives of pharma companies at Pragathi Bhavan here on Friday. He urged the medical fraternity to explore these options.

---

The Task Force, constituted to procure necessary vaccines and medicines for Covid management, met the top management of various pharmaceutical companies. The team discussed various issues in-depth with the heads of pharma companies involved in producing Covid vaccines.

Among the issues discussed in the meeting were the progress in the development of various types of vaccines by different companies, their production capacities, and the availability of vaccines in the market.

The Minister assured the representatives of all help from the government to expedite various steps involved in the commercialisation of vaccines. Among those participated in the meeting were representatives from Natco Pharma, Biological E Ltd, Bharath Biotech, Serum Institute of India, Sanofi India, Virchow Biotech, Zydus Cadila, Hetero Drugs, Gland Pharma, Indian Immunologicals, and Dr Reddys Labs.

Meanwhile, as part of its corporate social responsibility, the TSIIC contributed Rs 1.19 crore towards Covid mitigation activities in the State. A cheque was handed over by EV Narasimha Reddy, Managing Director-TSIIC, to Rahul Bojja, Commissioner of State Disaster Management Authority, in the presence of Commerce and Industries Minister KT Rama Rao, and Principal Secretary, Industries, Jayesh Ranjan.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

---